NCT06517888View on ClinicalTrials.gov

Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 17, 2025

Primary Completion Date

August 31, 2029

Study Completion Date

August 31, 2029

Conditions
Vestibular Schwannoma
Interventions
COMBINATION_PRODUCT

AAVAnc80-antiVEGF via Akouos Delivery Device

AAVAnc80-antiVEGF is a sterile suspension intended to be administered via intracochlear administration as a single dose using the Akouos Delivery Device

Trial Locations (4)

21205

RECRUITING

Johns Hopkins Hospital, Baltimore

37232

RECRUITING

Vanderbilt Bill Wilkerson Center, Nashville

55905

RECRUITING

Mayo Clinic, Rochester

75390

RECRUITING

University of Texas Southwestern, Dallas

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Akouos, Inc.

INDUSTRY